Luxana Biotech, Inc. announces that it has entered into a license agreement with Summit Pharmaceuticals International Corporation (President: Katsuya Okuyama, Head Office: Chiyoda-ku, Tokyo) for the manufacture and sale of Luxana Biotech’s artificially modified nucleic acid amidite.

Please check here for details.